Confirming the validity of the ARC-HBR criteria in patients presenting with ACS: the first step in reducing bleeding risk

Rev Esp Cardiol (Engl Ed). 2022 May;75(5):360-363. doi: 10.1016/j.rec.2021.11.005. Epub 2022 Jan 31.
[Article in English, Spanish]
No abstract available

MeSH terms

  • Humans
  • Percutaneous Coronary Intervention*
  • Platelet Aggregation Inhibitors
  • Risk Assessment
  • Risk Factors
  • Treatment Outcome


  • Platelet Aggregation Inhibitors